Matthew Cryer

Matt Cryer

Matthew Cryer

Prior to co-founding KP Biosciences Matthew worked with neuropharmacology and medical device developmental research groups, and conducted public markets research. He also worked as a financial analyst at TetraGene, an oncology biotechnology company, and was instrumental in the execution of valuation and market analysis efforts in preparation for a Series A. Since the inception of KP Biosciences Matthew negotiated and executed the F4-4 license from BYU, managed the early-stage pox and acyclovir-resistant herpes programs, and raised pre-seed working capital.